Insider · CIK 0001790965
Column Group III Gp, LP
owner
Files at SRZN (Surrozen, Inc./DE), TNYA (Tenaya Therapeutics, Inc.). First filing Mar 7, 2025, latest Mar 28, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 0
$37M bought, $0 sold
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
SRZN: Surrozen, Inc./DE
SRZNOct 9, 2026 · close 29.69
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
TNYA: Tenaya Therapeutics, Inc.
TNYAOct 9, 2026 · close 0.58
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | SRZNbuy Surrozen, Inc./DE | $12M 1,034,482 shares | +272% | - | |
| 50Moderate | Tenaya Therapeutics, Inc. | $25M 35,714,284 shares | +263% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Common Stockindirect: By The Column Group III, LP | +323,886 | $11.60 | $3.8M | 704,332 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Common Stockindirect: By The Column Group III-A, LP | +365,769 | $11.60 | $4.2M | 795,411 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Common Stockindirect: By The Column Group Opportunity III, LP | +344,827 | $11.60 | $4.0M | 344,827 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series A Common Warrantsderivativeindirect: By The Column Group III, LP | -90,897 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Series A Common Warrantsderivativeindirect: By The Column Group III, LP | +90,897 | - | - | 90,897 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series A Common Warrantsderivativeindirect: By The Column Group III-A, LP | -102,651 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Series A Common Warrantsderivativeindirect: By The Column Group III-A, LP | +102,651 | - | - | 102,651 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series B Common Warrantsderivativeindirect: By The Column Group III, LP | -98,870 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Series B Common Warrantsderivativeindirect: By The Column Group III, LP | +98,870 | - | - | 98,870 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series B Common Warrantsderivativeindirect: By The Column Group III-A, LP | -111,656 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Series B Common Warrantsderivativeindirect: By The Column Group III-A, LP | +111,656 | - | - | 111,656 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series C Common Warrantsderivativeindirect: By The Column Group III, LP | -352,225 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series C Common Warrantsderivativeindirect: By The Column Group III-A, LP | -397,773 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series D Common Warrantsderivativeindirect: By The Column Group III, LP | -352,225 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | HExpiration of long derivative Series D Common Warrantsderivativeindirect: By The Column Group III-A, LP | -397,773 | - | - | 0 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Series E Common Warrantsderivativeindirect: By The Column Group III, LP | +161,943 | - | - | 161,943 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Series E Common Warrantsderivativeindirect: By The Column Group III-A, LP | +182,884 | - | - | 182,884 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Series E Common Warrantsderivativeindirect: By The Column Group Opportunity II, LP | +172,414 | - | - | 172,414 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Second Tranche Units (Right to Buy)derivativeindirect: By The Column Group III, LP | +485,830 | - | - | 485,830 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Second Tranche Units (Right to Buy)derivativeindirect: By The Column Group III-A, LP | +548,653 | - | - | 548,653 | Mar 28, 2025 |
| Mar 26, 2025 | SRZN Surrozen, Inc./DE | POpen-market purchase Second Tranche Units (Right to Buy)derivativeindirect: By The Column Group Opportunity II, LP | +517,241 | - | - | 517,241 | Mar 28, 2025 |
| Mar 5, 2025 | TNYA Tenaya Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +35,714,284 | $0.70 | $25M | 49,313,559 | Mar 7, 2025 |
| Mar 5, 2025 | TNYA Tenaya Therapeutics, Inc. | POpen-market purchase Series A Warrant (right to buy)derivativeindirect: See Footnote | +35,714,284 | - | - | 35,714,284 | Mar 7, 2025 |
| Mar 5, 2025 | TNYA Tenaya Therapeutics, Inc. | POpen-market purchase Series B Warrant (right to buy)derivativeindirect: See Footnote | +17,857,142 | - | - | 17,857,142 | Mar 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.